Health Care [ 7/12 ] | Biotechnology [ 56/74 ]
NASDAQ | Common Stock
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome.
The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.
Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 26 | 0.59 Increased by +162.11% | 0.68 Decreased by -13.24% |
| Mar 11, 26 | 0.80 Increased by +162.99% | 0.21 Increased by +272.09% |
| Nov 4, 25 | 0.47 Increased by +125.68% | 0.05 Increased by +840.00% |
| Aug 6, 25 | -0.09 Increased by +84.21% | -0.64 Increased by +85.94% |
| Jun 6, 25 | -0.95 Decreased by -61.02% | -0.93 Decreased by -2.43% |
| Mar 4, 25 | -1.27 Decreased by -284.85% | -1.08 Decreased by -17.91% |
| Nov 5, 24 | -1.83 Decreased by -92.63% | -0.63 Decreased by -190.48% |
| Aug 7, 24 | -0.57 Increased by +29.63% | -0.60 Increased by +5.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 94.60 M Increased by +N/A% | 31.38 M Increased by +171.68% | Increased by +33.17% Decreased by N/A% |
| Dec 31, 25 | 91.73 M Increased by +N/A% | 43.36 M Increased by +177.45% | Increased by +47.27% Decreased by N/A% |
| Sep 30, 25 | 66.02 M Increased by +N/A% | 26.01 M Increased by +133.95% | Increased by +39.40% Decreased by N/A% |
| Jun 30, 25 | 32.66 M Increased by +N/A% | -4.71 M Increased by +78.46% | Decreased by -14.42% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -43.77 M Decreased by -104.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -55.98 M Decreased by -395.59% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -76.62 M Decreased by -605.42% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -21.85 M Decreased by -157.86% | Decreased by N/A% Decreased by N/A% |